Nissan Presage

Presage Announces FDA Study May Proceed to Evaluate Pre-GMP Drug Candidate in CIVO Phase 0 Clinical Trial

Retrieved on: 
Tuesday, January 16, 2024

The drug candidate, PBA-0405, is owned by Poland-based biopharmaceutical company, Pure Biologics, and represents the earliest stage material to date that will be evaluated in patients in a CIVO Phase 0 clinical trial.

Key Points: 
  • The drug candidate, PBA-0405, is owned by Poland-based biopharmaceutical company, Pure Biologics, and represents the earliest stage material to date that will be evaluated in patients in a CIVO Phase 0 clinical trial.
  • PBA-0405 is a ROR1-targeting compound that has been engineered to induce tumor cell killing by cytotoxic immune cells.
  • "We are very excited by this first opportunity to evaluate pre-GMP material in partnership with Pure Biologics," said Patrick Gray, PhD, Presage CEO.
  • "Our partnership with Presage was key in achieving this milestone and we eagerly await the first insights into drug efficacy and impact on the tumor microenvironment."

Presage to Present at AACR 2023 - Core CIVO Technology Reveals Unexpected Effects of an Investigational Ubiquitination Inhibitor on Checkpoint Blockade

Retrieved on: 
Monday, April 17, 2023

In an independent study, Presage's innovative multiplexed trackable microdosing platform (CIVO®) was used to introduce an investigational ubiquitin inhibitor (TAK-243) alone and in combination with anti-PD1.

Key Points: 
  • In an independent study, Presage's innovative multiplexed trackable microdosing platform (CIVO®) was used to introduce an investigational ubiquitin inhibitor (TAK-243) alone and in combination with anti-PD1.
  • The resulting data demonstrated that TAK-243 has potential to increase anti-tumor immunogenicity and prime tumors for response to immune checkpoint inhibition.
  • After AACR 2023, Presage Biosciences' CIVO technology will be further showcased at two events:
    The 4th Annual International Phase-0/Microdosing Stakeholder Meeting in Boston, MA on April 24th.
  • Presage is featured speaker, panel moderator and sponsor at this year's event;
    Life Science Innovation Northwest (LSINW) in Seattle, WA on April 25.

Presage Announces Collaboration with Pure Biologics to Investigate Oncology Agents in Early Development with CIVO® Technology

Retrieved on: 
Monday, February 6, 2023

Presage's CIVO platform will be used to evaluate drug mechanism of action, potential indicators of efficacy, and drug combinations.

Key Points: 
  • Presage's CIVO platform will be used to evaluate drug mechanism of action, potential indicators of efficacy, and drug combinations.
  • "We see this partnership as a tremendous opportunity for Presage to continue innovating and delivering key pharmacodynamic insights into a partner's early-stage oncology assets."
  • "Their CIVO platform will allow us to introduce our novel agents directly into patient tumors and provide the first real clues about drug efficacy."
  • The collaboration with Pure Biologics comes on the heels of Presage's recently completed Phase 0 clinical trials (NCT04065555 and NCT04541108) with Takeda Pharmaceutical Company evaluating immune-oncology drugs alone and in combination in head and neck cancer patients.

Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics

Retrieved on: 
Tuesday, March 2, 2021

This investment brings the total equity raised by Presage to date to $35 million.

Key Points: 
  • This investment brings the total equity raised by Presage to date to $35 million.
  • "Presage's CIVO technology and unique approach to early anticancer drug evaluation represent a potential solution that typical preclinical models cannot address."
  • Presage has ongoing collaborations with Takeda and other large pharmaceutical organizations for Phase 0 trials with CIVO.
  • Presage also partners with oncology-focused pharmaceutical companies through strategic alliances to provide preclinical data to discover effective drug combinations.

Tracker Capital Acquires Presage Security

Retrieved on: 
Wednesday, January 20, 2021

Tracker Capital Management, LLC (Tracker Capital), a stage-agnostic venture capital investor that principally invests in emerging technologies, today announced that one of its affiliates has acquired controlling interest in Presage Security (Presage).

Key Points: 
  • Tracker Capital Management, LLC (Tracker Capital), a stage-agnostic venture capital investor that principally invests in emerging technologies, today announced that one of its affiliates has acquired controlling interest in Presage Security (Presage).
  • Tracker Capitals investment and partnership will significantly enhance our ability to deliver innovative solutions to our customer base, said Mark Oliver, Founder and Chief Executive Officer of Presage.
  • David Robertson, Managing Director at Tracker Capital, commented: We are pleased to partner with Presage, particularly at this exciting time in the companys development.
  • Tracker Capital was founded by Stephen Feinberg, Co-Founder and Co-Chief Executive Officer of Cerberus Capital Management, L.P., as a separate and independent investment vehicle focused on early-stage investments.

Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer

Retrieved on: 
Tuesday, July 17, 2018

The company also announced that Dr. Richard Klinghoffer, currently Presage's Chief Scientific Officer, has been named Chief Executive Officer.

Key Points: 
  • The company also announced that Dr. Richard Klinghoffer, currently Presage's Chief Scientific Officer, has been named Chief Executive Officer.
  • Dave Johnson, Chairman of the Board, said, "We are thrilled to have closed this financing with long-time Presage strategic partners, Takeda and Celgene.
  • Johnson continued, "Rich has demonstrated astute scientific leadership and has always played a central role in the company's strategic direction.
  • On behalf of the board, I want to thank him for his valuable service to Presage."